MAPT and Alzheimer disease: Materials and methods: To investigate the prophylactic treatment effect of T-006 for AD, T-006 (3 mg/kg) was applied as preventive treatment to two AD-related transgenic mouse models, 2xTg (APP/PS1) (2-month-old; n = 8–10) and 3xTg (APP/PS1/MAPT) (4-month-old; n = 8–10) for 6 and 8 months, respectively.